CL2024002490A1 - Sal y forma cristalina del compuesto inhibidor de dipeptidil peptidasa - Google Patents

Sal y forma cristalina del compuesto inhibidor de dipeptidil peptidasa

Info

Publication number
CL2024002490A1
CL2024002490A1 CL2024002490A CL2024002490A CL2024002490A1 CL 2024002490 A1 CL2024002490 A1 CL 2024002490A1 CL 2024002490 A CL2024002490 A CL 2024002490A CL 2024002490 A CL2024002490 A CL 2024002490A CL 2024002490 A1 CL2024002490 A1 CL 2024002490A1
Authority
CL
Chile
Prior art keywords
salt
crystalline form
inhibitor compound
dipeptidyl peptidase
peptidase inhibitor
Prior art date
Application number
CL2024002490A
Other languages
English (en)
Spanish (es)
Inventor
Fan Jiang
Dou Ying
ZHU Fengfei
Gong Zheng
Original Assignee
Haisco Pharmaceuticals Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haisco Pharmaceuticals Pte Ltd filed Critical Haisco Pharmaceuticals Pte Ltd
Publication of CL2024002490A1 publication Critical patent/CL2024002490A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cooling Or The Like Of Semiconductors Or Solid State Devices (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2024002490A 2022-02-22 2024-08-20 Sal y forma cristalina del compuesto inhibidor de dipeptidil peptidasa CL2024002490A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210160862 2022-02-22

Publications (1)

Publication Number Publication Date
CL2024002490A1 true CL2024002490A1 (es) 2024-12-13

Family

ID=87764787

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024002490A CL2024002490A1 (es) 2022-02-22 2024-08-20 Sal y forma cristalina del compuesto inhibidor de dipeptidil peptidasa

Country Status (13)

Country Link
US (1) US20250188067A1 (cg-RX-API-DMAC7.html)
EP (1) EP4484414A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025508792A (cg-RX-API-DMAC7.html)
KR (1) KR20240153351A (cg-RX-API-DMAC7.html)
CN (1) CN118660873A (cg-RX-API-DMAC7.html)
AU (1) AU2023225835A1 (cg-RX-API-DMAC7.html)
CA (1) CA3243683A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002490A1 (cg-RX-API-DMAC7.html)
IL (1) IL314852A (cg-RX-API-DMAC7.html)
MX (1) MX2024010180A (cg-RX-API-DMAC7.html)
TW (1) TW202342466A (cg-RX-API-DMAC7.html)
WO (1) WO2023160542A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202407225B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025506307A (ja) * 2022-02-22 2025-03-07 ハイスコ ファーマスーティカル プライベート リミテッド 含窒素複素環化合物の調製方法
JP2026503035A (ja) 2023-01-06 2026-01-27 インスメッド インコーポレイテッド 新規な可逆性dpp1阻害剤及びその用途
WO2025162472A1 (en) 2024-01-31 2025-08-07 Insmed Incorporated Linear dipeptidyl peptidase 1 inhibitors and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7902181B2 (en) * 2007-12-12 2011-03-08 Astrazeneca Ab Compounds 010
NO2699580T3 (cg-RX-API-DMAC7.html) * 2014-01-24 2018-02-24
PL4129989T3 (pl) * 2020-08-26 2025-02-24 Haisco Pharmaceuticals Pte. Ltd. Pochodna nitrilu działająca jako inhibitor dipeptydylopeptydazy 1 i jej zastosowanie
CN114106005B (zh) * 2020-08-26 2025-08-01 西藏海思科制药有限公司 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途
CN114591315A (zh) * 2020-12-04 2022-06-07 瑞石生物医药有限公司 一种组织蛋白酶c小分子抑制剂
WO2022166721A1 (zh) * 2021-02-05 2022-08-11 南京明德新药研发有限公司 含1,4-氧杂氮杂环庚烷的并环类衍生物

Also Published As

Publication number Publication date
EP4484414A1 (en) 2025-01-01
TW202342466A (zh) 2023-11-01
IL314852A (en) 2024-10-01
AU2023225835A1 (en) 2024-10-03
MX2024010180A (es) 2024-08-27
ZA202407225B (en) 2025-12-17
KR20240153351A (ko) 2024-10-22
CA3243683A1 (en) 2025-01-22
JP2025508792A (ja) 2025-04-10
US20250188067A1 (en) 2025-06-12
WO2023160542A1 (zh) 2023-08-31
EP4484414A4 (en) 2026-01-28
CN118660873A (zh) 2024-09-17

Similar Documents

Publication Publication Date Title
MX2024010180A (es) Sal y forma cristalina del compuesto inhibidor de dipeptidil peptidasa.
MX2020012965A (es) Combinacion, composicion y preparacion de compuesto farmaceutico que comprende activador de glucocinasa e inhibidor de dpp-iv, metodo de preparacion y uso del mismo.
SA522432955B1 (ar) Kras g12c مثبطات
JOP20240210A1 (ar) مثبطات kras
CO2026005655A2 (es) Inhibidor de pan-kras y uso del mismo en medicinas
MX2019008853A (es) Metodos para la administracion de ciertos inhibidores de proteina transportadora transportador de monoamina vesicular-2 (vmat2).
CO6220933A2 (es) Formulaciones de dosis unitaria y metdods para el tratamiento de la trombosis con un inhibidor oral del facror xa
MX2020013116A (es) Sales y cristales novedosos.
CU23808B7 (es) Formas de presentación farmacéutica sólidas de administración oral con liberación rápida de principio activo
MX2024014861A (es) Inhibidor de la prmt5 de tres anillos fusionados que contiene nitrogeno, y metodo de preparacion del mismo y uso farmaceutico del mismo
PE20220017A1 (es) Inhibidores del kcnt1 y metodos de uso
ECSP21051825A (es) COMPUESTOS Y SU USO PARA EL TRATAMIENTO DE LA DEFICIENCIA DE a1-ANTITRIPSINA
ECSP099780A (es) Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
PE20170705A1 (es) Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion)
MX2017000628A (es) Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia.
CO6220969A2 (es) Adminsitracion semanal de inhibidores de peptidasa de dipeptidilo
GEP20207095B (en) Fused bicyclic heteroaryl derivatives having activity as phd inhibitors
CL2021001629A1 (es) Compuestos de halo-alilamina y uso de los mismos
UY38592A (es) Forma cristalina de 1-(1-oxo-1,2-dihidroisoquinolin-5-il)-5-(trifluorometil)-n-(2-(trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida monohidratada, proceso para su preparación y composiciones farmacéuticas que las contienen
RU2017117559A (ru) Бензопроизводные с шестичленным кольцом в качестве ингибитора dpp-4 и их применение
CL2022000875A1 (es) Inhibidores del factor d del complemento para administración oral
MX2022001759A (es) Composicion farmaceutica oral que contiene compuesto heterociclico.
MX390507B (es) Compuestos de amida y su uso.
CL2021002107A1 (es) Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria.